Sanofi Aventis Us patent expiration

1. Ambien Cr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6514531 SANOFI AVENTIS US Controlled-release dosage forms comprising zolpidem or a salt thereof
Dec, 2019

(4 years ago)

US6514531

(Pediatric)

SANOFI AVENTIS US Controlled-release dosage forms comprising zolpidem or a salt thereof
Jun, 2020

(4 years ago)




Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 02 September, 2005

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of AMBIEN CR before it's drug patent expiration?
More Information on Dosage

AMBIEN CR family patents

Family Patents

2. Apidra patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6221633 SANOFI AVENTIS US Insulin derivatives having a rapid onset of action
Jun, 2018

(6 years ago)

US7696162 SANOFI AVENTIS US Zinc-free and low-zinc insulin preparations having improved stability
Mar, 2022

(2 years ago)

US7452860 SANOFI AVENTIS US Zinc-free and low-zinc insulin preparations having improved stability
Mar, 2022

(2 years ago)

US6960561 SANOFI AVENTIS US Zinc-free and low-zinc insulin preparations having improved stability
Jan, 2023

(1 year, 5 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Oct 24, 2011

Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient

Market Authorisation Date: 16 April, 2004

Treatment: Method of treating a patient suffering from diabetes mellitus

Dosage: INJECTABLE

More Information on Dosage

APIDRA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Apidra Solostar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6221633 SANOFI AVENTIS US Insulin derivatives having a rapid onset of action
Jun, 2018

(6 years ago)

US7696162 SANOFI AVENTIS US Zinc-free and low-zinc insulin preparations having improved stability
Mar, 2022

(2 years ago)

US7452860 SANOFI AVENTIS US Zinc-free and low-zinc insulin preparations having improved stability
Mar, 2022

(2 years ago)

US6960561 SANOFI AVENTIS US Zinc-free and low-zinc insulin preparations having improved stability
Jan, 2023

(1 year, 5 months ago)

US9775954 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(4 months ago)

US9610409 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(4 months ago)

US9827379 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(4 months ago)

US9526844 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(4 months ago)

US9604008 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(4 months ago)

US9408979 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(4 months ago)

US8603044 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(4 months ago)

US9233211 SANOFI AVENTIS US Relating to a pen-type injector
Mar, 2024

(4 months ago)

US8556864 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(4 months ago)

US9011391 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(3 months ago)

US8992486 SANOFI AVENTIS US Pen-type injector
Jun, 2024

(a month ago)

US9604009 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(28 days from now)

US9533105 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(29 days from now)

US9623189 SANOFI AVENTIS US Relating to drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(a month from now)

US9561331 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(a month from now)

US8512297 SANOFI AVENTIS US Pen-type injector
Sep, 2024

(a month from now)

US8679069 SANOFI AVENTIS US Pen-type injector
Apr, 2025

(8 months from now)

US7918833 SANOFI AVENTIS US Pen-type injector
Sep, 2027

(3 years from now)

US9717852 SANOFI AVENTIS US Cartridge holder and pen-type injector
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Oct 24, 2011

Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient

Market Authorisation Date: 16 April, 2004

Treatment: Method of treating a patient suffering from diabetes mellitus; Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glyce...

Dosage: INJECTABLE

More Information on Dosage

APIDRA SOLOSTAR family patents

Family Patents

4. Aubagio patent expiration

AUBAGIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5459163 SANOFI AVENTIS US Medicament to combat autoimmune diseases
Oct, 2012

(11 years ago)

US5679709 SANOFI AVENTIS US Medicaments to combat autoimmune diseases
Oct, 2014

(9 years ago)

US6794410 SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Sep, 2026

(2 years from now)

US6794410

(Pediatric)

SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Mar, 2027

(2 years from now)

US8802735 SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Sep, 2030

(6 years from now)

US8802735

(Pediatric)

SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Mar, 2031

(6 years from now)

US9186346 SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Feb, 2034

(9 years from now)

US9186346

(Pediatric)

SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Aug, 2034

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 12, 2017
M(M-61) Apr 30, 2024
Pediatric Exclusivity(PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

NCE-1 date: 31 October, 2023

Market Authorisation Date: 12 September, 2012

Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction...

Dosage: TABLET

How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage

AUBAGIO family patents

Family Patents

5. Avalide patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5994348 SANOFI AVENTIS US Pharmaceutical compositions containing irbesartan
Jun, 2015

(9 years ago)

US5994348

(Pediatric)

SANOFI AVENTIS US Pharmaceutical compositions containing irbesartan
Dec, 2015

(8 years ago)




Drugs and Companies using HYDROCHLOROTHIAZIDE; IRBESARTAN ingredient

Market Authorisation Date: 30 September, 1997

Treatment: NA

Dosage: TABLET

How can I launch a generic of AVALIDE before it's drug patent expiration?
More Information on Dosage

AVALIDE family patents

Family Patents

6. Avapro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6342247 SANOFI AVENTIS US Pharmaceutical compositions containing irbesartan
Jun, 2015

(9 years ago)

US6342247

(Pediatric)

SANOFI AVENTIS US Pharmaceutical compositions containing irbesartan
Dec, 2015

(8 years ago)




Drugs and Companies using IRBESARTAN ingredient

Market Authorisation Date: 30 September, 1997

Treatment: NA

Dosage: TABLET

How can I launch a generic of AVAPRO before it's drug patent expiration?
More Information on Dosage

AVAPRO family patents

Family Patents

7. Eloxatin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5290961 SANOFI AVENTIS US Platinum compound and process of preparing same
Jan, 2013

(11 years ago)

US5338874 SANOFI AVENTIS US Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity
Apr, 2013

(11 years ago)

US5290961

(Pediatric)

SANOFI AVENTIS US Platinum compound and process of preparing same
Jul, 2013

(11 years ago)

US5338874

(Pediatric)

SANOFI AVENTIS US Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity
Oct, 2013

(10 years ago)

US5716988 SANOFI AVENTIS US Pharmaceutically stable preparation of oxaliplatinum
Aug, 2015

(8 years ago)

US5716988

(Pediatric)

SANOFI AVENTIS US Pharmaceutically stable preparation of oxaliplatinum
Feb, 2016

(8 years ago)

US5420319 SANOFI AVENTIS US Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same
Aug, 2016

(7 years ago)

US5420319

(Pediatric)

SANOFI AVENTIS US Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same
Feb, 2017

(7 years ago)




Drugs and Companies using OXALIPLATIN ingredient

Market Authorisation Date: 09 August, 2002

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of ELOXATIN before it's drug patent expiration?
More Information on Dosage

ELOXATIN family patents

Family Patents

8. Jevtana Kit patent expiration

JEVTANA KIT's oppositions filed in EPO
JEVTANA KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7241907 SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Dec, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5698582 SANOFI AVENTIS US Compositions containing taxane derivatives
Jul, 2012

(12 years ago)

US5438072 SANOFI AVENTIS US Taxoid-based compositions
Nov, 2013

(10 years ago)

US6387946 SANOFI AVENTIS US Methods for treating pathological conditions of abnormal cell proliferation
Mar, 2016

(8 years ago)

US6331635 SANOFI AVENTIS US Taxoids, their preparation and pharmaceutical compositions containing them
Mar, 2016

(8 years ago)

US6372780 SANOFI AVENTIS US Methods of treating cell lines expressing multidrug resistance P-glycoprotein
Mar, 2016

(8 years ago)

US5847170 SANOFI AVENTIS US Taxoids, their preparation and pharmaceutical compositions containing them
Mar, 2016

(8 years ago)

US5847170

(Pediatric)

SANOFI AVENTIS US Taxoids, their preparation and pharmaceutical compositions containing them
Sep, 2021

(2 years ago)

US7241907

(Pediatric)

SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Jun, 2026

(1 year, 10 months from now)

US10583110 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(6 years from now)

US8927592 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(6 years from now)

US10716777 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(6 years from now)

US8927592

(Pediatric)

SANOFI AVENTIS US Antitumoral use of cabazitaxel
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2015
M(M-201) May 17, 2020
M(M-209) Sep 14, 2020
Pediatric Exclusivity(PED) Nov 17, 2020
M(M-128) Dec 18, 2023

Drugs and Companies using CABAZITAXEL ingredient

NCE-1 date: 18 November, 2019

Market Authorisation Date: 17 June, 2010

Treatment: Treatment of cancer; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlo...

Dosage: SOLUTION

How can I launch a generic of JEVTANA KIT before it's drug patent expiration?
More Information on Dosage

JEVTANA KIT family patents

Family Patents

9. Ketek patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USD459798 SANOFI AVENTIS US Pill tablet
Sep, 2015

(8 years ago)

US5635485 SANOFI AVENTIS US Erythromycin compounds
Apr, 2018

(6 years ago)




Drugs and Companies using TELITHROMYCIN ingredient

Market Authorisation Date: 09 February, 2005

Treatment: Treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis caused by susceptible strains of designated microorganisms in patients 18 years and o...

Dosage: TABLET

More Information on Dosage

KETEK family patents

Family Patents

10. Lantus patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5656722 SANOFI AVENTIS US A21 -, B30 - modified insulin derivatives having an altered action profile
Aug, 2014

(9 years ago)

US5656722

(Pediatric)

SANOFI AVENTIS US A21 -, B30 - modified insulin derivatives having an altered action profile
Feb, 2015

(9 years ago)

US7713930 SANOFI AVENTIS US Acidic insulin preparations having improved stability
Jun, 2023

(1 year, 1 month ago)

US7476652 SANOFI AVENTIS US Acidic insulin preparations having improved stability
Jul, 2023

(11 months ago)

US7713930

(Pediatric)

SANOFI AVENTIS US Acidic insulin preparations having improved stability
Dec, 2023

(7 months ago)

US7476652

(Pediatric)

SANOFI AVENTIS US Acidic insulin preparations having improved stability
Jan, 2024

(5 months ago)

US7918833 SANOFI AVENTIS US Pen-type injector
Sep, 2027

(3 years from now)

US7918833

(Pediatric)

SANOFI AVENTIS US Pen-type injector
Mar, 2028

(3 years from now)




Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 27 April, 2007

Treatment: Treatment of diabetes mellitus

Dosage: INJECTABLE

More Information on Dosage

LANTUS family patents

Family Patents

11. Lantus Solostar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9827379 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(4 months ago)

US9526844 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(4 months ago)

US9233211 SANOFI AVENTIS US Relating to a pen-type injector
Mar, 2024

(4 months ago)

US9610409 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(4 months ago)

US9604008 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(4 months ago)

US8603044 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(4 months ago)

US9775954 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(4 months ago)

US9408979 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(4 months ago)

US8556864 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(4 months ago)

US9011391 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(3 months ago)

US8992486 SANOFI AVENTIS US Pen-type injector
Jun, 2024

(a month ago)

US9604009 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(28 days from now)

US9533105 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(29 days from now)

US9623189 SANOFI AVENTIS US Relating to drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(a month from now)

US9561331 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(a month from now)

US8512297 SANOFI AVENTIS US Pen-type injector
Sep, 2024

(a month from now)

US8679069 SANOFI AVENTIS US Pen-type injector
Apr, 2025

(8 months from now)

US9717852 SANOFI AVENTIS US Cartridge holder and pen-type injector
Apr, 2033

(8 years from now)




Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 27 April, 2007

Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glycemic control in diabetes mellitus patients by use of a pen injec...

Dosage: INJECTABLE

More Information on Dosage

LANTUS SOLOSTAR family patents

Family Patents

12. Multaq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5223510 SANOFI AVENTIS US Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them
Jul, 2016

(7 years ago)

US8318800 SANOFI AVENTIS US Solid pharmaceutical compositions containing benzofuran derivatives
Jun, 2018

(6 years ago)

US7323493 SANOFI AVENTIS US Solid pharmaceutical composition containing benzofuran derivatives
Jun, 2018

(6 years ago)

US8410167 SANOFI AVENTIS US Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Apr, 2029

(4 years from now)

US9107900 SANOFI AVENTIS US Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality
Apr, 2029

(4 years from now)

US8602215 SANOFI AVENTIS US Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
Jun, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 01, 2014

Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient

NCE-1 date: 01 July, 2013

Market Authorisation Date: 01 July, 2009

Treatment: Reduction of the risk of hospitalization for atrial fibrillation; Treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by ...

Dosage: TABLET

How can I launch a generic of MULTAQ before it's drug patent expiration?
More Information on Dosage

MULTAQ family patents

Family Patents

13. Nasacort Aq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5976573 SANOFI AVENTIS US Aqueous-based pharmaceutical composition
Jul, 2016

(8 years ago)

US7977045 SANOFI AVENTIS US Aqueous-based pharmaceutical composition
Jul, 2016

(8 years ago)

US6143329 SANOFI AVENTIS US Aqueous-based pharmaceutical composition
Jul, 2016

(8 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 19, 2011

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 20 May, 1996

Treatment: Treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults and children two years of age and older

Dosage: SPRAY, METERED

More Information on Dosage

NASACORT AQ family patents

Family Patents

14. Oforta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7547776 SANOFI AVENTIS US Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5%
Dec, 2018

(5 years ago)

US7148207 SANOFI AVENTIS US Oral fludara of high-purity formulation with quick release of active ingredient
Dec, 2022

(1 year, 6 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Dec 18, 2011
Orphan Drug Exclusivity(ODE) Dec 18, 2015

Drugs and Companies using FLUDARABINE PHOSPHATE ingredient

Market Authorisation Date: 18 December, 2008

Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)

Dosage: TABLET

More Information on Dosage

OFORTA family patents

Family Patents

15. Plavix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6429210 SANOFI AVENTIS US Polymorphic clopidogrel hydrogenesulphate form
Jun, 2019

(5 years ago)

US6504030 SANOFI AVENTIS US Polymorphic form of clopidogrel hydrogen sulphate
Jun, 2019

(5 years ago)

US6429210

(Pediatric)

SANOFI AVENTIS US Polymorphic clopidogrel hydrogenesulphate form
Dec, 2019

(4 years ago)

US6504030

(Pediatric)

SANOFI AVENTIS US Polymorphic form of clopidogrel hydrogen sulphate
Dec, 2019

(4 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-61) May 06, 2014
Pediatric Exclusivity(PED) Nov 06, 2014

Drugs and Companies using CLOPIDOGREL BISULFATE ingredient

Market Authorisation Date: 17 November, 1997

Treatment: NA

Dosage: TABLET

How can I launch a generic of PLAVIX before it's drug patent expiration?
More Information on Dosage

PLAVIX family patents

Family Patents

16. Taxotere patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5750561 SANOFI AVENTIS US Compositions containing taxane derivatives
Jul, 2012

(12 years ago)

US5698582 SANOFI AVENTIS US Compositions containing taxane derivatives
Jul, 2012

(12 years ago)

US5714512 SANOFI AVENTIS US Compositions containing taxane derivatives
Jul, 2012

(12 years ago)

US5750561

(Pediatric)

SANOFI AVENTIS US Compositions containing taxane derivatives
Jan, 2013

(11 years ago)

US5714512

(Pediatric)

SANOFI AVENTIS US Compositions containing taxane derivatives
Jan, 2013

(11 years ago)

US5698582

(Pediatric)

SANOFI AVENTIS US Compositions containing taxane derivatives
Jan, 2013

(11 years ago)

US5438072 SANOFI AVENTIS US Taxoid-based compositions
Nov, 2013

(10 years ago)

US5438072

(Pediatric)

SANOFI AVENTIS US Taxoid-based compositions
May, 2014

(10 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-61) May 13, 2013
Pediatric Exclusivity(PED) Nov 13, 2013

Drugs and Companies using DOCETAXEL ingredient

Market Authorisation Date: 03 August, 2010

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of TAXOTERE before it's drug patent expiration?
More Information on Dosage

TAXOTERE family patents

Family Patents